Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EPS (Basic): 2014-2025

Historic EPS (Basic) for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $1.17.

  • Ascendis Pharma A's EPS (Basic) fell 38.11% to $1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.76, marking a year-over-year decrease of 220.46%. This contributed to the annual value of -$7.07 for FY2024, which is 23.17% up from last year.
  • Per Ascendis Pharma A's latest filing, its EPS (Basic) stood at $1.17 for Q3 2025, which was up 61.37% from $0.72 recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's EPS (Basic) peaked at $3.79 during Q4 2022, and registered a low of -$13.88 during Q4 2021.
  • Its 3-year average for EPS (Basic) is $0.54, with a median of $1.89 in 2024.
  • Per our database at Business Quant, Ascendis Pharma A's EPS (Basic) surged by 127.28% in 2022 and then tumbled by 903.57% in 2024.
  • Over the past 5 years, Ascendis Pharma A's EPS (Basic) (Quarterly) stood at -$13.88 in 2021, then skyrocketed by 127.28% to $3.79 in 2022, then slumped by 56.22% to $1.66 in 2023, then tumbled by 903.57% to -$13.31 in 2024, then plummeted by 38.11% to $1.17 in 2025.
  • Its EPS (Basic) was $1.17 in Q3 2025, compared to $0.72 in Q2 2025 and $1.66 in Q1 2025.